Applications published 13 May 2009

Galenic formulations of aliskiren
Novartis 2056790*

Pharmaceutical compsns including vitamin D and corticosteroid
Teva Pharmaceutical Industries 2056791*

• Drug delivery systems comprising solid solutions of weakly basic drugs
Eurand 2056792*

• Free base gacyclidine nanoparticles
Neurosystec 2056793*

• Multistage delivery of active agents
Board of Regents of the University of Texas; Tasciotti, Ennio 2056794*

• Process for preparing pramipexole dihydrochloride tablets with high storage stability
Boehringer Ingelheim Pharma 2056795*

• Lyophilised preparation
Asubio Pharma 2056796*

• Controlled release system and method for manufacturing the same
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 2056797*

• Sorbic acid analogue co-crystals
Amgen 2056798*

• Compsns and methods for treating or preventing glaucoma or progression thereof
Bausch & Lomb 2056799*

• Therapy procedure for drug delivery for trigeminal pain
Board of Trustees of the Leland Stanford Junior University 2056800*

• Ruthenium II compounds
The University Court of the University of Edinburgh 2056801*

• Anti-diabetes compsn containing chicoric acid and/or one of the metabolites thereof
Centre National de la Recherche Scientifique (CNRS) 2056802*

• Thiol-based agents for reducing toxicities associated with medical procedures employing radiographic contrast agents
Oregon Health Science University 2056803*

• Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
Action Medicines 2056804*

• Use of 2,5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases
Action Medicines 2056805*

• Use of certain chemical compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins
Max-Planck-Gesellschaft zur Foerderung der Wissenschaften; Heinrich-Heine-Universitaet Duesseldorf 2056806*

• Treatment of inflammatory diseases
University of Chicago 2056807*

• Small molecule potentiator of hormonal therapy for breast cancer
The Regents of the University of California 2056808*

• Ophthalmic percutaneous absorption type preparation
Senju Pharmaceutical 2056809*

• Thiourea compounds
National Health Research Institutes 2056810*

• Modafinil-based treatment for premature ejaculation
Neurohealing Pharmaceuticals 2056811*

• Methods of treating angiogenesis and treating angiogenesis-related diseases
Abraxis BioScience 2056812*

• 2,5-dihydroxybenzene compounds for the treatment of rosacea
Action Medicines 2056813*

• 2,5-dihydroxybenzene compounds for the treatment of psoriasis
Action Medicines 2056814*

• Use of 2,5-dihydroxybenzene derivatives for treating dermatitis
Action Medicines 2056815*

• Lipoxin-A4-analogues for the treatment and prevention of intestinal fibrosis
Bayer Schering Pharma 2056816*

• Benzofuran and banothiophene derivatives useful in the treatment of cancers of the central nervous system
Bayer HealthCare 2056817*

• Compsns and methods for neuroprotection
The Johns Hopkins University 2056818*

• Cholesterol lowering drug combination
Duke University 2056819*

• A pharmaceutical compsn for the treatment of a fungal skin disorder and a method for preparation thereof
Stichting voor de Technische Wetenschappen 2056820*

• Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders
Novartis 2056821*

• Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
SGX Pharmaceuticals 2056822*

• 8-hydroxyquinoline compounds and methods thereof
Wyeth 2056823*

• Topical ceramide compsns and methods of use
Lipo Chemicals 2056824*

• Use of opioid formulations in needle-less drug delivery devices
Euro-Celtique 2056825*

• Compsns and methods for increasing blood platelet levels in humans
Akarx 2056826*

• Method of inducing tumour apoptosis by increasing nitric oxide levels
Universitaetsklinikum Freiburg 2056827*

• Sulfonylated piperazines as cannabinoid-1 receptor modulators
Merck 2056828*

• Using P13K and MEK modulators in treatments of cancer
Exelixis 2056829*

• Compsns useful especially for treatment or prevention of metabolic syndrome
Faron Pharmaceuticals 2056830*

• Use of PKC inhibitors in particular indolylmaleimide derivatives in ocular diseases
Novartis; Novartis Pharma 2056831*

• Comsps, suitable for oral adminstration, comprising a triazolo [4,5-D]pyrimidin derivate
AstraZeneca 2056832*

• Derivatives or uric and thiouric acid for oxidative stress-related diseases
Government of the United States of America, Represented by the Secretary, Department of Health and Human Services 2056833*

• Methods and compsns for increasing patient tolerability during myocardial imaging methods
CV Therapeutics 2056834*

• Pharmaceutical compsns and uses thereof
ActivBiotics Pharma 2056835*

• Powder formulations for inhalation containing enantiomerically pure beta-agonists
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 2056836*

• Aerosol formulation for the inhalation of beta-agonists
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 2056837*

• Combination therapy for treatment of immune disorders
Schering 2056838*

• Combination approaches to cancer treatment
Auckland Uniservices 2056839*

• Compsns, devices and methods for treatment of Huntington's disease through intracranial delivery of sirna
Medtronic 2056840*

• Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
Medtronic; Alnylam Pharmaceuticals 2056841*

• Modified-galactosyl ceramides for staining and stimulating natural killer T cells
The Scripps Research Institute; Brigham Young University; The University of Chicago 2056842*

• Use of C7 sugars in prevention and treatment of mycoses
Laboratoires Expanscience 2056843*

• Novel macrolides and ketolides having antimicrobial activity
Wockhardt Research Centre 2056844*

• Structure and use of 5"-phosphate oligonucleotides
Hartmann, Gunther 2056845*

• Salivary substitute
Unither Development 2056846*

• Dermal drops
ABR 2056847*

• Use of extracts for the treatment of viral disorders
Johnson & Johnson Consumer Companies 2056848*